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Abstract
Background Laparoscopic Roux-en-Y gastric bypass
(LRYGB) can dramatically ameliorate type 2 diabetes
mellitus (T2DM) in morbidly obese patients. However,
there is little evidence supporting the effectiveness of
LRYGB in low body mass index (BMI) patients. The study
was designed to evaluate the safety and results of LRYGB
for achieving T2DM remission in patients with BMI in the
range of 25–35 kg/m2.
Methods Twenty-two patients (two men and 20 women)
with T2DM underwent LRYGB. Data on patient demo-
graphics, BMI, co-morbidities, and details of diabetes
mellitus, including disease duration, family history, medi-
cation use, and remission, were prospectively collected and
analyzed.
Results The mean age was 47 years (range, 28–63 years),
mean BMI was 30.81 (range, 25.00–34.80 kg/m2), and
mean duration of T2DM onset was 6.57 years (range,
1–20 years). Sixteen (72.27%) patients had a family
history of T2DM. There was no mortality, but two (9%)
patients experienced complications: an early gastrojeju-
nostomy hemorrhage and frequent loose stools that
required revision surgery. At 12 months, 14 (63.6%)
patients showed T2DM remission, six (27.3%) showed
glycemic control, and two (9.1%) showed improvement.
The group achieving remission had a higher BMI (p=0.001),
younger age (p=0.002), and shorter duration of diabetes
(p=0.001). These three factors may be predictors of diabetes
resolution at 12 months.
Conclusion Early intervention in low-BMI patients yields
better remission rates because age, BMI, and duration of
T2DM predict glycemic outcomes.
Keywords Laparoscopic Roux-en-Y gastric bypass .
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Introduction
Diabetes is a chronic progressive disease and is undoubt-
edly the most common endocrine disorder worldwide.
According to projections by WHO, its prevalence will
reach a staggering 334 million people worldwide by the
year 2025 [1]. Currently, medical treatment, including diet,
exercise, and anti-diabetic medications, is the mainstay for
managing type 2 diabetes mellitus (T2DM). However, there
is increasing evidence that surgery can help achieve
complete remission, especially in morbidly obese patients
with diabetes [2]. The positive effects of bariatric surgery
on the remission of T2DM are well established [3–5].
Several conventional and experimental surgical operations
can dramatically ameliorate T2DM. While the benefits of
gastric bypass surgery for treating obese patients with
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diabetes have been discussed in the literature, there is little
evidence to support the effectiveness of this surgery in
T2DM patients with low body mass index (BMI) [6].
Our study aims to prospectively evaluate the results of
laparoscopic Roux-en-Y gastric bypass (LRYGB) surgery
in patients with a BMI of 25–35 kg/m2 in order to achieve
T2DM remission.
Material and Methods
The study was conducted with the approval of the ethics
committee and institutional review board of the E-Da
Hospital (EMRP-097-106). All patients gave written
informed consent after being made aware of the current
standards of treatment for T2DM and understanding the
risks and benefits associated with the procedure. Inclu-
sion criteria for this study were as follows: age from 18
to 65 years, BMI from 25 to 34.9 kg/m2, and poorly
controlled T2DM as reflected by glycosylated hemoglobin
(HbA1C) level of ≥7%. Diagnosis of T2DM was based on
the criteria of the American Diabetes Association (ADA)
and was considered valid if established by an endocrinol-
ogist or diabetes specialist [7]. Before the operation,
patients were assessed by a specialized team, including a
surgeon, an endocrinologist, an anesthetist, a psychiatrist,
and a dietician. All patients underwent routine a preoper-
ative work-up and counseling in addition to a detailed
diabetic work-up. Patients younger than 18 years or older
than 65 years; those planning a pregnancy within 2 years
after entry into this study; and those with established
diagnoses of type 1 diabetes, latent autoimmune diabetes
in adults, malignancy, debilitating disease, unresolved
psychiatric illness, or substance abuse were excluded from
the study.
We employed the previously reported LRYGB technique
[8]. Data were collected prospectively and entered into a
database. We collected data on patient demographics; BMI;
co-morbidities; and details of the diabetes mellitus status,
including the duration of disease, family history, and
medication use. Operative details recorded were operation
time, duration of hospitalization, and complications noted
until the last follow-up session. In addition to the data from
routine preoperative investigations, data on fasting plasma
glucose (FPG), fasting C-peptide, and HbA1c levels were
collected. Follow-up visits were scheduled at 1 week and at
1, 3, 6, 9, and 12 months after surgery. Postoperative data
collected included levels of FPG, fasting C-peptide and
HbA1c, medication usage, and BMI.
The goals for glycemic and blood pressure controls were
based on the criteria established by the ADA [9]. If patients
were not taking anti-diabetic medications and had a normal
FPG of <100 mg/dL and a normal HbA1c of <6%, their
condition was considered resolved. Those with an HbA1c
of ≤7% despite no use of anti-diabetic medications were
said to have achieved glycemic control. If the FPG
decreased by >25 mg/dL or the HbA1c reduced >1%, the
patients’ condition was considered to have improved.
Surgery was considered to have failed if glycemic indices
showed no significant improvement or worsened or if a
patient required additional anti-diabetic medication.
Statistical Analysis
The means and standard deviations (SDs) were computed
for continuous variables and evaluated using independent
t tests. Categorical variables are presented as numbers and
percentages. Follow-up comparisons were analyzed using
the paired t test. When 20% of the cells had expected
values of <5, Fisher’s exact test was used instead. All
statistics were two-tailed and were calculated with SPSS
statistical software (version 15.0; SPSS Inc., Chicago, IL,
USA). Values of p<0.05 were considered statistically
significant.
Results
In this study, 22 patients (two men and 20 women) with
T2DM underwent LRYGB between December 2008 and
January 2010. The mean age was 47.36 (11.16) years
(range, 28–63 years). The preoperative mean BMI was
30.81 (3.24) (range, 25.00–34.80 kg/m2); 10 (45.5%) of the
patients had BMIs of 25–29.99 kg/m2, and 12 (54.5%) had
BMIs of 30–34.99 kg/m2. The mean duration from the
onset of T2DM was 6.57 (6.34) years (range, 1–20 years).
Sixteen (72.27%) patients had a family history of T2DM.
Oral hypoglycemic agents (OHGA) were used by 15
(68.1%) patients before the operation. One (4.5%) patient
required insulin therapy. Three patients (13.6%) were
receiving both insulin and OHGA. Three (13.6%) other
patients had discontinued medication for no reason. Fifteen
(68.1%) patients had multiple co-morbidities. Fourteen
(63.6%) patients had hyperlipidemia; 13 (59%), hyperten-
sion; 10, (45.4%) steatohepatitis; and two, (9%) gouty
arthritis.
We were able to successfully complete LRYGB in all
patients. The mean operative time was 72.8 (18.2) min
(range, 45–134 min). The mean duration of hospitalization
was 2.41 (0.73) days (range, 2–4 days). There was no
mortality, but two (9%) patients developed complications:
One patient had an early hemorrhage at the gastrojejunos-
tomy site, and the other had frequent loose stools.
All of the 22 patients were followed up for 12 months.
The changes in BMI at 1 year in comparison to the mean
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preoperative BMI were significant (p<0.001), and the mean
BMI dropped from 30.8 (2.9) preoperatively to 24.4 (2.6) at
the sixth month and 23.7 (1.6) at the 12th month;
nevertheless, the BMIs remained within the normal range
(Fig. 1).
LRYGB resulted in a marked improvement in the
biochemical markers of diabetes. Fasting C-peptide levels
were assessed in 10 patients with a mean BMI of 29.4
(24.7–34.7), and they significantly dropped after surgery,
from preoperative values of 3.74 (2.44) ng/ml to 1.94 (1.29)
ng/ml at the first month (p=0.002), 1.90 (0.92) ng/ml at the
third month (p=0.009), 1.88 (0.82) ng/ml at the sixth month
(p=0.013), and 1.88 (1.07) ng/ml at 1 year (p=0.005).
Figures 2 and 3 demonstrate the improvement in FPG and
HbA1c, respectively, during the course of 1 year. FPG and
HbA1c significantly decreased from their preoperative
values of 204.2 (88.3) mg/dL and 9.2% to 113.5 (42.5)
mg/dL and 6.3% (p<0.001) at 6 months and to 103.5 (27.6)
mg/dL and 5.9% (p<0.007) at 12 months, respectively. FPG
was normalized in seven (31.4%) patients at the first month,
and HbA1c was normalized in 14 (63.6%) patients at the
sixth month. At the 12th month, 14 (63.6%) patients
achieved remission of T2DM, six (27.3%) showed glycemic
control, and two (9.1%) showed improvement. Twenty
patients (90.3%) did not need any medication. Only two
patients still needed OHGA, and they had used a combina-
tion of OHGA and insulin therapy before the operation. All
patients showed either an improvement or remission with
regard to glycemic control. We found that the group that
achieved remission after 12 months seemed to have higher
BMI (p=0.001), younger age (p=0.002), and a shorter
duration of diabetes (p=0.001) (Table 1).
In addition, we did an analysis of the remission rate on
the basis of the Asia-Pacific surgical criteria of morbid
obesity, according to which the BMI should be ≥32 [10].
There were 14 patients whose BMI was <32, of whom only
six (42.8%) patients achieved remission after surgery. The
other eight patients achieved glycemic control or showed
improvement in diabetes mellitus. To compare with the
100% remission rate of eight patients with a BMI of >32,
the result is significantly different (p=0.018).
Discussion
Diabetes encompasses a group of chronic progressive
metabolic diseases that are characterized by hyperglycemia
resulting from defects in insulin secretion or action or both
Fig. 1 Changes in mean BMI
over time
Fig. 2 Changes in mean fasting
plasma glucose (FPG) over time
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[11]. Diabetes is grouped into four clinical classes, and
T2DM is the most common form of diabetes worldwide.
In the medical management of T2DM, the treatment goal
is to achieve glycemic control in order to reduce compli-
cations; this is different from the potential novel end point
of euglycemia that metabolic surgery offers [12]. A meta-
analysis that summarizes diabetic outcomes of 3,188
patients reports a resolution rate of 80.3% with LRYGB,
95.1% after biliopancreatic diversion (BPD), and 56.7%
after laparoscopic adjustable gastric banding (LAGB) in
morbidly obese individuals [5]. The effects of bariatric
procedures on the metabolic outcomes in individuals who
are operated outside the NIH guidelines (i.e., patients with a
BMI of <35 kg/m2) have been both interesting and
controversial [13]. Since the first report on the amelioration
of diabetes after subtotal gastrectomy in non-obese indi-
viduals by Friedmann et al., interest in metabolic surgery
and the body of evidence supporting its use continues to
grow [14–19]. Metabolic surgery—in particular, surgery for
the amelioration of T2DM—marks the dawn of a new era
in surgery. Although the exact mechanisms that govern the
resolution of diabetes after surgery are poorly understood,
innovative procedures based on the current understanding
of mechanisms, such as duodenojejunal bypass and ileal
interposition, are the subject of investigational studies on
the amelioration of diabetes [20–23]. LRYGB is known to
achieve sustainable resolution of diabetes in morbidly obese
individuals [24]. This technique has been employed for
ameliorating diabetes in patients with low BMI, and the
short-term results from three such studies have been
encouraging [17, 25, 26].
Bariatric procedures are typically designed to induce
weight loss. Many critics have discussed the extrapolation
of the metabolic results of such procedures for justifying
Fig. 3 Changes in mean HbA1c
over time
Parameters Remission, N=14 Glycemic control/improvement, N=8 p value
Age (years)a 41.69 (10.77) 55.56 (5.028) 0.002*
Gender (%)b 0.494
Women 11 (84.6) 9 (100.0)
Men 2 (15.4) 0 (0.0)
BMI (kg/m2)a 32.37 (2.57) 28.06 (2.30) 0.001***
Glucose (mg/dL)a 192.92 (81.47) 231.22 (94.56) 0.338
HbA1C (%)a 9.02 (2.10) 9.52 (1.95) 0.568
Total cholesterol (ng/dL)a 195.07 (104.47) 191.56 (41.93) 0.925
Triglyceride (ng/dL)a 170.08 (46.23) 196.56 (43.41) 0.188
HDLC (ng/dL)a 44.58 (6.72) 46.29 (9.03) 0.674
LDLC (ng/dL)a 128.83 (42.02) 113.57 (25.00) 0.397
Duration of DM (years) 3.08 (2.71) 11.22 (6.91) 0.001***
DM family history (%)c 0.376
No 3 (23.1) 4 (44.4)
Yes 10 (76.9) 5 (55.6)
OHGA (%)b 0.616
No 3 (23.1) 1 (11.1)
Yes 10 (76.9) 8 (88.9)
Insulin therapy (%)b 1.000
No 11 (84.6) 7 (77.8)
Yes 2 (15.4) 2 (22.2)
Table 1 Preoperative predictors
of T2DM remission
Continuous variables are
presented as mean (standard
deviation) and categorical
variables are presented as
number (%)
BMI Body mass index;
HbA1C xglycosylated
hemoglobin;
HDL high density lipoprotein;
LDL low density lipoprotein;
OHGA oral hypoglycemic agent
*p<0.05, statistically significant
difference between the two
groups
a p values were calculated by
independent t test
b p values were calculated by
Fisher’s exact test
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their application in T2DM patients with BMIs below the
cut-off as per NIH guidelines. In this study, all patients
experienced weight loss because of which they were in
either the normal or overweight category; none were
underweight. Other studies concerning LRYGB performed
on patients with low BMIs corroborate the finding of a less
dramatic postoperative change in BMI [17, 26]. A possible
explanation postulated by Scopinaro et al. is that a
homeostatic mechanism permits weight loss relative to the
amount of calories for which the procedure facilitates its
absorption. Furthermore, there is blunting of weight loss
[19].
The mean operating time and duration of hospitalization
in our study were 72.86 min and 2.41 days, respectively—
half the corresponding values (153.6 min and 4.5 days,
respectively) for morbidly obese patients undergoing
LRYGB [8]. We believe that the shorter operating time
was the result of a lower BMI because our surgical
technique remained unchanged. Although expansion of
LRYGB criteria to include low-BMI patients with T2DM
is attractive, the issue of safety needs to be addressed. There
was no mortality in the present study, and the overall
morbidity of 9% was similar to that of 10.3% for
malabsorptive/restrictive procedures in low-BMI patients,
as mentioned in a report by Fried et al. [27]. Early
hemorrhage from the gastrojejunal anastomosis occurred
in one patient and was conservatively managed with blood
transfusion. Another female patient experienced frequent
loose stools after the procedure. In a study by Lee et al.,
6.2% and 2.2% of the patients had minor and major
complications, respectively [26]. The overall complication
rate in our study appears reasonable. However, T2DM is
well-known to adversely affect many systems depending on
the duration and control of hyperglycemia. It must be
stressed that during patient selection, the additional risk of
complications related to T2DM should be considered.
Contrary to the findings of other studies that suggest that
FPG can be normalized within days after bariatric surgery
in morbidly obese patients, as a result of the change in
insulin resistance [28], in this study, we found that FPG
improved after surgery but failed to return to normal
immediately. However, as expected, the FPG and HbA1C
values gradually declined over time, with two patients
achieving euglycemia at 1 week; seven, at 1 month; and 14,
at 6 months after surgery. We also observed that those who
did not achieve remission at 6 months did not do so at the
12th month either. Studies on the timing of the restoration
of glucose metabolism after surgery suggest that the T2DM
remission occurs as a primary specific independent effect of
this surgery, rather than secondary to the observed weight
loss [29]. The early low resolution rates and continued
improvement in glycemic parameters noted in the present
study suggest that in addition to high insulin resistance,
low-BMI patients may also have a relative deficiency of
insulin. We found that the mean fasting C-peptide level was
3.74 ng/ml in 10 of our patients, but very low, i.e., from 1.9
to 2.3 ng/ml, in six patients. Lee et al. reported that 76.5% of
patients with BMIs below 35 kg/m2 met the ADA target for
the treatment of T2DM at 1 year after surgery [26]. Hall et
al. reported that 68.4% of the 98 patients using medications
were off all diabetic medication after LRYGB [30]. Overall,
20 of our patients discontinued medication after the surgery,
and only two needed to use OHGA agents at low doses;
none of the patients needed insulin. The remission and
glycemic rates reported in the present study are 90.9%.
We assessed the age at which presentation predicts
negative outcomes: elderly patients with T2DM for a
prolonged duration were less likely to achieve euglycemia
at 12 months. Similarly, Hall et al. reported that their
patients who had diabetes for shorter durations had higher
rates of remission [30]. Schauer et al. found that the
magnitude of weight loss appears to increase the likelihood
of resolution in obese individuals with diabetes [24].
However, in our study, the resolution of T2DM was not
related to changes in BMI, although a higher preoperative
BMI did predict remission. This finding confirms that the
normalization of glycemic indices is not related to weight
loss. Furthermore, the relatively poor outcomes related to
increasing age and duration of diabetes support the notion
that early surgical intervention is necessary in overweight
and grade 1 obese patients with diabetes. Although this trial
involved limited cases, the mean BMI was 32.4 in patients
who achieved remission, and complete remission was
observed in patients with a BMI of >32; this result precisely
correlated with the Asia-Pacific surgical criteria. We
recommend that further comparative studies be conducted
according to the Asia-Pacific surgical criteria for diabetic
remission.
Conclusions
Our study shows that LRYGB for patients with BMI in the
range of 25–35 kg/m2 is safe and feasible, with low early
morbidity. Age, BMI, and the duration of T2DM predict
glycemic outcomes at the 12th month. This study supports
the notion that LRYGB can result in good remission rates in
low-BMI patients with diabetes and should be considered
as a method of early intervention.
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